Clinical Trials Browser

Phase 1/2 × Withdrawn × Inotuzumab Ozogamicin × Clear all

NCT03851081 2022-01-28

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Phase 1/2 Withdrawn

Burkitt Lymphoma